NSCLC: S-1 noninferior to docetaxel as 2nd, 3rd line therapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • S-1 offers similar OS, PFS, and response rates as docetaxel for second- or third-line therapy for patients with advanced NSCLC, with less neutropenia and febrile neutropenia. 

Why this matters

  • Phase 2 S-1 monotherapy as second-line treatment for advanced NSCLC study overal...